Livzon Pharmaceutical Group Inc.
000513
Helyezés a részvények között
#4689
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and... Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturing and commercialization. The company's operations encompass a diverse range of finished drug products, active pharmaceutical ingredients (APIs), and chemical intermediates, primarily serving the Chinese market while also engaging in international exports. Its pharmaceutical portfolio includes treatments such as Ilaprazole enteric coated tablets for duodenal ulcers and reflux esophagitis, Laprazole sodium injection for managing peptic ulcer bleeding, Leuprorelin Acetate Microspheres for injection, and Urofollitropin injection for anovulation and fertility support. Livzon also produces Perospirone Hydrochloride for schizophrenia, Anti-viral Granules targeting upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, spontaneous sweating, and vertigo, and provides supportive care for lung and stomach cancer patients. Beyond therapeutic drugs, Livzon Pharmaceutical Group develops and distributes a variety of diagnostic reagents. These include kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid tests for human immunodeficiency virus type 1, antinuclear antibody test kits, interferon-gamma release assay kits, and rapid tests for mycoplasma pneumoniae IgM antibodies. The company's extensive offerings further extend to biochemical drugs, microbiological preparations, biologics, traditional Chinese medicine formulations, pharmaceutical raw materials, and antibiotics.
Részvényárfolyam
$3.90
Piaci kapitalizáció
$3.17B
Változás (1 nap)
-3.49%
Változás (1 év)
-25.88%
Ország
CN
Kereskedés Livzon Pharmaceutical Group Inc. (000513)
Kategória
Healthcare
Bevétel a(z) Livzon Pharmaceutical Group Inc. (000513) részvényhez
Bevétel ekkor: Jun 2026 TTM: $1.61B
Livzon Pharmaceutical Group Inc. legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi árbevétele (TTM) $1.61B. 2024 évben a vállalat $1.62B árbevételt ért el, amely csökkenés a 2023 évben elért $1.76B árbevételhez képest. Az árbevétel az a teljes összeg, amit a vállalat termékek vagy szolgáltatások eladásából generál. A nyereséggel ellentétben ebből nem vonódnak le költségek.
Livzon Pharmaceutical Group Inc. bevételtörténete 2001 és 2026 között
Bevétel az év végén
| Év | Bevétel | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $1.61B | -5.45% |
| 2025 | $1.70B | 5.18% |
| 2024 | $1.62B | -7.84% |
| 2023 | $1.76B | -4.09% |
| 2022 | $1.83B | -3.54% |
| 2021 | $1.90B | 17.86% |
| 2020 | $1.61B | 19.49% |
| 2019 | $1.35B | 4.63% |
| 2018 | $1.29B | -1.76% |
| 2017 | $1.31B | 18.97% |
| 2016 | $1.10B | 8.10% |
| 2015 | $1.02B | 13.90% |
| 2014 | $895.10M | 17.55% |
| 2013 | $761.43M | 20.40% |
| 2012 | $632.40M | 26.05% |
| 2011 | $501.72M | 21.45% |
| 2010 | $413.11M | 8.65% |
| 2009 | $380.22M | 26.03% |
| 2008 | $301.69M | 26.02% |
| 2007 | $239.41M | 17.50% |
| 2006 | $203.75M | 1.14% |
| 2005 | $201.46M | 7.23% |
| 2004 | $187.88M | -14.19% |
| 2003 | $218.94M | 13.17% |
| 2002 | $193.46M | 14.69% |
| 2001 | $168.68M | 0.00% |
Hasonló cégek vagy versenytársak bevétele
| Vállalat | Bevétel | Bevételkülönbség | Ország |
|---|---|---|---|
| $23.54B | 1,362.30% |
DE
|
|
| $23.73B | 1,374.71% |
DE
|
|
| $29.24B | 1,716.72% |
JP
|
|
| $5.85B | 263.40% |
CH
|
|
| $6.34B | 294.06% |
IN
|
